Search results
Novavax, Inc. (NVAX) vs. Its Peers: A Comparison – News Heater
NewsHeater· 2 weeks agoThere are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 2 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.” The public float for NVAX is 132.98M ...
These Biotech Stocks Could Soar 120% and 295%, According to Wall Street
Motley Fool via Yahoo Finance· 2 weeks agoThe average Wall Street estimate is that Novavax shares may soar 295% over the coming year. But will...
The path to a better Tuberculosis vaccine runs through Montana
Daily Montanan via Yahoo News· 5 hours agoA team of Montana researchers is playing a key role in the development of a more effective vaccine...
Less than half of nursing home residents are up to date with their COVID-19 vaccines, study finds:...
Yahoo Life Style via AOL· 2 weeks agoHere’s your go-to guide with everything you need to know about COVID-19, including testing expanding...
Flu vs COVID: Stark Disparity in Vaccination and Deaths
Medscape· 3 days agoIn the first half of 2023, COVID-19 killed 42,670 people in the United States, while the flu killed...
Is Moderna Stock A Buy On Its Eye-Popping First-Quarter Sales Beat?
Investor's Business Daily· 2 days agoFurther, the companies are running a late-stage study in non-small cell lung cancer patients. One...
Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Investor's Business Daily· 3 days agoThough it has a booster Covid shot, like rivals Moderna and Novavax, analysts don't expect sales to...
Europe Strengthens Future Disease Defense
Medscape· 1 week agoA network of health security agencies has been established in Europe and Central Asia to bolster the region's preparedness to meet future disease...